Tech Company Financing Transactions
Normunity Funding Round
On 10/25/2022, Normunity landed $65 million in Series A funding from Canaan Partners, Osage University Partners and Sanofi Ventures.
Transaction Overview
Company Name
Announced On
10/25/2022
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its emerging pipeline of immune normalizers into the clinic. Proceeds from the financing will also be used to build on multiple discovery platforms in the Lieping Chen lab to pursue additional mechanisms that block normal anti-cancer immunity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
520 West Campus Drive
West Haven, CT 06477
USA
West Haven, CT 06477
USA
Phone
Website
Email Address
Overview
We are uncovering something big in immuno-oncology. It's called normunity. That's the name of our company, and we are pioneering cancer-fighting medicines that target novel immuno-oncology mechanisms. It's also our new approach that treats cancer by restoring normunity -- or the state of normal immunity -- by removing cancer's barriers to normal immune system function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel Humphrey
Chief Financial Officer
Scott Phillips
Chief Scientific Officer
William LaRochelle
Browse more venture capital transactions:
Prev: 10/25/2022: Yoom venture capital transaction
Next: 10/25/2022: RapidSOS venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs